Lv2
168 积分 2023-02-16 加入
Phase Ib of repotrectinib plus osimertinib in patients with EGFR-mutated advanced non-small cell lung cancer
2天前
求助中
EGFR S442 ectodomain mutation confers cetuximab resistance that can be overcome by ERBB2 blockade with trastuzumab-deruxtecan
2天前
已完结
Association between the 21-gene recurrence score assay and risk of locoregional recurrence in node-negative, estrogen receptor-positive breast cancer: results from NSABP B-14 and NSABP B-20
4天前
已完结
Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer
4天前
已完结
Global and regional cancer burden attributable to modifiable risk factors to inform prevention
5天前
已完结
Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
5天前
已完结
Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
5天前
已完结
Capivasertib in Hormone Receptor–Positive Advanced Breast Cancer
5天前
已完结
皖公网安备34019202002308
